Trial
NCT03690141
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Effector Therapeutics
Collaborators
—
Condition
Castrate-resistant Prostate Cancer (CRPC)
Intervention
eFT508
Why stopped
Terminated early due to a lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-06-21